-- 
XTL Rises to 2-Week High on Seeking Orphan Status for Drug

-- B y   R o n i t   G o o d m a n
-- 
2011-04-21T12:28:40Z

-- http://www.bloomberg.com/news/2011-04-21/xtl-rises-to-3-week-high-on-seeking-fda-orphan-status-for-drug.html
XTL Biopharmaceuticals Ltd. (XTLB)  climbed
to the highest level in more than two weeks after the
biopharmaceutical company sought orphan drug status for its
myeloma drug from the U.S. Food and Drug Administration.  The shares advanced 6.2 percent to 0.637 shekel, the
highest since April 5, giving the Nes Ziona, Israel-based
company a market value of 130 million shekels ($38 million).  To contact the reporter on this story:
{Ronit Goodman} in Tel Aviv at 
 rgoodman9@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  